29 September 2022

Gout Spondyloarthritis

No heart attack, no worries?

11 August 2022

Communicable Diseases Gout Spondyloarthritis

How big is the infection risk for JAKi vs TNFi?

14 July 2022

Communicable Diseases Gout

Encouraging real-world data for JAKi and cancer

23 June 2022

Biologics Gout PBAC

‘Game-changer’ on horizon for alopecia areata

5 May 2022

Analgesics Gout

Alopecia hope in common arthritis drug

5 May 2022

COVID-19 Gout PBS Rheumatoid Arthritis Spondyloarthritis

Flare rates low after covid vax

10 March 2022

Ankylosing Spondylitis Gout Juvenile Arthritis Pharmacy Guild of Australia Ross River Virus

Promising findings on steroid-sparing options for PMR and GCA

3 February 2022

COVID-19 Gout Lupus Scleroderma

Updated covid treatment guidelines and immunosuppressed patients

27 January 2022

Gout Research Spondyloarthritis

Real-world data on JAKi and CV outcomes

22 December 2021

COVID-19 Gout

Rheumatology Republic Year in Review

16 December 2021

Gout Spondyloarthritis

JAKi: To cycle or switch?

9 November 2021

Ankylosing Spondylitis Biologics Gout Pharmacy Guild of Australia

What’s on the way for GCA?

28 October 2021

Biologics Gout Research

Spare a thought for the sperm

30 September 2021

Biologics Gout

JAKi debate: the view from across the ditch

23 September 2021

Biologics Gout

Have JAK inhibitors failed to meet their promise?

2 September 2021

Gout PBAC

FDA black box blow for all JAK inhibitors